Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Thoracic Neoplasms × Vinorelbine × Clear all

Phase

Status

Sponsor Class

OTHER 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 41 Carcinoma, Non-Small-Cell Lung 28 Lung Neoplasms 8 Triple Negative Breast Neoplasms 6 Neoplasm Metastasis 6 Neoplasms 5 Uterine Cervical Neoplasms 4 Recurrence 2 Mesothelioma 2 Lymphoma, Non-Hodgkin 2 Carcinoma 2 Adenocarcinoma of Lung 2 Adenocarcinoma 2 Thoracic Neoplasms 1 Stomach Neoplasms 1 Sarcoma 1 Parkinson Disease 4, Autosomal Dominant Lewy Body 1 Ovarian Neoplasms 1 Nonhematologic Malignancies 1 Non-Squamous Non-Small Cell Lung Cancer 1 Non - Small Cell Lung Cancer NSCLC 1 Neuroendocrine Tumors 1 NSCLC 1 Metatropic dwarfism 1 Metastatic HER2-positive Breast Cancer 1 Lung Diseases 1 Lethal Congenital Contracture Syndrome 2 1 HR+HER2- Breast Cancer 1 HER2-positive Advanced Breast Cancer 1 Desmoplastic Small Round Cell Tumor 1

Interventions

Carboplatin 8 Pemetrexed 6 pembrolizumab 5 osimertinib 4 entinostat 3 Paclitaxel 3 Gemcitabine 3 selpercatinib 2 pralsetinib 2 durvalumab 2 Erlotinib Hydrochloride 2 Cisplatin 2 taletrectinib 1 sotorasib 1 repotrectinib 1 patritumab 1 necitumumab 1 napabucasin 1 ficlatuzumab 1 exemestane 1 efineptakin alfa 1 cobimetinib 1 ceralasertib 1 camrelizumab 1 atezolizumab 1 alectinib 1 Vinorelbine 1 TNFSF10 protein, human 1 Patient Reported Outcome Measures 1 Nivolumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05583188 2024-07-19

VIGOR

Galvanize Therapeutics, Inc.

Phase 4 Terminated

Lung Diseases, Lung Neoplasms, Thoracic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡